A Phase 2 Trial of EO2040, a miCrobiaL-derived Peptide therApeUtic Vaccine, in Combination With Nivolumab, for Treatment of Patients With Circulating Tumor DNA-dEfined Minimal Residual Disease of Colorectal Cancer Stage II, III, or IV After Completion of Curative Therapy (the "CLAUDE" Study)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EO 2040 (Primary) ; Nivolumab (Primary) ; Montanide ISA-51
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms CLAUDE
Sponsors Enterome

Most Recent Events

19 Dec 2024 Status changed to discontinued.
12 Mar 2024 Status changed from recruiting to completed.
24 Nov 2023 The trial has been completed in Germany (End Date: 02 Oct 2023), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight